MedTrace Logo

PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor

NCT02071017 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2014-02-25

No results posted yet for this study

Summary

Background and purpose: In adult, the half of the CNS neoplasms are metastatic, and high grade astrocytomas and oligodendrogliomas are most frequent malignant tumors among the last half. Recently, integrated MRI-PET (Biograph mMR, Siemens, Germany) was introduced, and can provide simultaneous whole body MRI-PET imaging as well as brain-specific advanced imaging (e.g. DWI, PWI, and DCE). The purpose of the present study is to evaluate whether the simultaneous MRI-PET acquisition can improve the diagnostic yield for the patients initially presented with brain tumors, and predict the prognosis in the patients diagnosed with primary high graded astrocytoma or oligodendroglioma.

Conditions

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • SeungHong Choi, MD, PhD · Seoul National University Hospital(Radiology)

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02071017 on ClinicalTrials.gov